USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ACIONT, INC.
City: SALT LAKE CITY
State: UT
Zip+4: 84103-
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (801) 359-3461

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $433,703.00 3
SBIR Phase II $2,029,592.00 1

Award List:

NON-INVASIVE BLOOD PHENYLALANINE MONITOR

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Abdelhalim Ghanem
Award Amount: $159,509.00
Abstract:
DESCRIPTION (provided by applicant): Phenylketonuria (PKU) is a genetic deficiency of phenylalanine hydroxylase (PAH). Without PAH, the patient with PKU cannot metabolize phenylalanine (PHE) to tyrosine. The resulting accumulation of PHE and the accumulation of phenylpyruvate by a secondary… More

IMPROVED NON-INVASIVE BLOOD GLUCOSE MONITORING DEVICE

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Abdelhalim Ghanem
Award Amount: $140,992.00
Abstract:
The accurate measurement of blood glucose concentration is important in the management of diabetes. Current methods of glucose monitoring involve piercing the skin and collecting blood samples for analysis up to four times daily or more. Even the non-invasive Glucowatch tm glucose monitoring system… More

Non-Invasive Drug Delivery to Treat Posterior Uveitis

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: David J. Miller
Award Amount: $133,202.00
Abstract:
Intermediate and posterior uveitis cause 10% of blindness in the U.S. The mainstay of therapy is to eradicate the infectious cause and to quell the inflammation with corticosteroids or immunosuppressants. Delivery of anti-inflammatory drugs to the posterior portion of the globe in therapeutic… More

Non-Invasive Treatment for Uveitis

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: William I. Higuchi – 801-359-3461
Award Amount: $2,029,592.00
Abstract:
DESCRIPTION (provided by applicant): The aim of this innovative proposal is to commercialize a non-invasive topical product that treats uveitis which is safe and easy to administer. Uveitis is the third leading cause of blindness in the United States. Heretofore, the primary treatment of… More